Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 16/20 | 0.59 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.51 |
| ▸ | CDC42 | P60953 | 2/20 | 0.50 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.50 |
| ▸ | PKN2 | Q16513 | 2/20 | 0.50 |
| ▸ | PARP1 | P09874 | 1/20 | 0.50 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1571812 | 0.85 | CSNK2A1 (0.58) | ROCK2MAP2K1CDC42ROCK1PKN2 | |
| SCHEMBL1412087 | 0.85 | ROCK2 (0.54) | ROCK2MAP2K1CDC42ROCK1PKN2 | |
| SCHEMBL12715912 | 0.85 | ROCK2 (0.54) | ROCK2MAP2K1CDC42ROCK1PKN2 | |
| SCHEMBL4000783 | 0.85 | ROCK2 (0.54) | ROCK2MAP2K1CDC42ROCK1PKN2 | |
| SCHEMBL12448944 | 0.85 | ROCK2 (0.57) | ROCK2MAP2K1CDC42ROCK1PKN2 | |
| SCHEMBL20882061 | 0.82 | ROCK2 (0.67) | ROCK2CDC42ROCK1PKN2 | |
| SCHEMBL20882071 | 0.82 | ROCK2 (0.55) | ROCK2MAP2K1CDC42ROCK1PKN2 | |
| SCHEMBL1536538 | 0.81 | MAP2K1 (0.56) | ROCK2MAP2K1CDC42ROCK1PKN2 | |
| SCHEMBL30037800 | 0.81 | ROCK2 (0.50) | ROCK2MAP2K1CDC42ROCK1PKN2 | |
| SCHEMBL25368500 | 0.79 | ALDH1A1 (0.50) | ROCK2MAP2K1CDC42ROCK1PKN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040122223-A1 | Non-natural nucleotides and dinucleotides | CELLTECH R & D LIMITED (GB) | 2004-06-24 | — | — | US | disclosed |
| EP-1368366-A1 | NON-NATURAL NUCLEOTIDES AND DINUCLEOTIDES | Celltech R & D Limited (GB) | 2003-12-10 | — | — | EP | disclosed |
| WO-2002062816-A1 | NON-NATURAL NUCLEOTIDES AND DINUCLEOTIDES | CELLTECH R & D LIMITED (GB) | 2002-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122223-A1 | Non-natural nucleotides and dinucleotides | P2RY1, P2RY11, P2RY13 | ROCK2 4486/4885MAP2K1 2217/4885CDC42 1023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.